精华制药(002349) - 2018 Q4 - 年度财报

Financial Performance - The company reported a total revenue of 814,180,908, with a cash dividend of 0.50 yuan per 10 shares (including tax) proposed for distribution to all shareholders[8]. - The company's operating revenue for 2018 was ¥1,354,705,881.53, representing a 20.86% increase compared to ¥1,120,920,317.81 in 2017[27]. - Net profit attributable to shareholders for 2018 was ¥229,665,275.60, a 31.00% increase from ¥175,319,960.72 in 2017[27]. - The net profit after deducting non-recurring gains and losses was ¥219,381,913.67, showing a significant increase of 73.47% compared to ¥126,463,286.74 in 2017[27]. - The company's cash flow from operating activities for 2018 was ¥83,430,076.44, up 9.89% from ¥75,922,623.52 in 2017[27]. - Total assets at the end of 2018 were ¥3,399,701,718.30, reflecting a 4.88% increase from ¥3,241,587,925.29 at the end of 2017[27]. - The weighted average return on equity for 2018 was 9.91%, an increase of 1.92% from 7.99% in 2017[27]. - The company reported a significant increase in sales expenses, totaling ¥169,038,336.34, which is a 19.98% increase compared to 2017[78]. - Research and development expenses for 2018 were ¥40,319,130.75, reflecting a 7.04% increase from the previous year[81]. Shareholder Information - The board of directors has approved the profit distribution plan, which includes no bonus shares being issued[8]. - The company plans to distribute a cash dividend of 0.50 yuan per 10 shares for the year 2018, amounting to 40,709,045.40 yuan, with retained earnings of 328,014,931.49 yuan[137]. - The company distributed a cash dividend of 0.50 yuan per 10 shares, totaling 42,029,483.10 yuan for the year 2017[136]. - The cash dividend per 10 shares is set at CNY 0.50, with a total share base of 814,180,908 shares for the distribution[140]. - The company has committed to distributing at least 30% of the average distributable profit over the past three years (2015-2017) in cash, contingent on profitability and cash flow[147]. Business Operations - The company has not reported any changes in its main business since its listing, indicating stability in operations[24]. - The company has not experienced any changes in its controlling shareholders since its listing, reflecting stability in ownership[26]. - The company has maintained its registered address and contact information without changes, ensuring consistency in communication[21][22]. - The company has established a strong quality control system, with four products certified by European COS and others passing FDA audits[49]. - The company is actively expanding into the healthcare and elderly care sectors as part of its strategic development plan[54]. - The company is actively exploring new retail models while enhancing online and offline marketing efforts[57]. - The company aims to become a well-known enterprise in the national pharmaceutical health industry by 2020, focusing on product advantages and core competitiveness[114]. Acquisitions and Investments - The company completed the acquisition of 51% equity in Su Xin Pharmaceutical for 16.065 million RMB, enhancing its business in pharmaceutical distribution and healthcare[54]. - The company made a significant equity investment of ¥16,065,000 in Jiangsu Suxin Pharmaceutical Co., Ltd., acquiring a 51% stake[100]. - The company signed an agreement for Jiangsu Senxuan Pharmaceutical Co., Ltd. to acquire 100% of the shares of Jinghua Pharmaceutical Group Nantong Co., Ltd. and 35.1821% of Nantong Senxuan Pharmaceutical Co., Ltd.[152]. Risk Management - The company acknowledges potential risks related to raw material procurement, sales price declines, product quality, and environmental safety[8]. - The company faces risks from fluctuations in raw material prices, which could significantly impact profitability[124]. - The company has implemented a flexible procurement strategy to mitigate risks associated with raw material supply shortages[124]. - The company anticipates increased competition due to national healthcare reforms and pricing policies, which may affect market position and profitability[123]. Compliance and Governance - The company emphasizes the importance of ensuring the accuracy and completeness of the financial report, with key personnel affirming its authenticity[6]. - The accounting firm Tianheng has been appointed for auditing, with key auditors being Min Zhiqiang and Wang Zhaogang[26]. - The company has committed to transparency and compliance with relevant laws and regulations regarding shareholding and profit distribution[146]. - The company confirmed that there are no integrity issues with its controlling shareholders or actual controllers[159]. - The company reported no penalties or rectification situations during the reporting period[158]. Social Responsibility - The company invested a total of 20.98 million yuan in poverty alleviation efforts during the reporting period[197]. - The company established standardized planting bases for traditional Chinese medicine in five national-level poverty counties, covering 27,560 acres and providing training for over 160 farmers[193]. - The company provided 30,000 yuan for healthcare resource investment in impoverished areas to improve local medical services[197]. - The company has created 62 job opportunities through its investment in the Longxi Baohengtang company[194]. - The company has conducted 22 training sessions for grassroots medical staff, improving their capabilities in traditional Chinese medicine[196]. Environmental Commitment - The company has a commitment to environmental protection and is classified as a key pollutant discharge unit by environmental authorities[199].